Artificial sight used for the first time in Europe

Article

A blind person's sight has been restored by surgeons at the University Hospitals of Geneva (HUG) for the first time in Europe using American technology.

A blind person's sight was restored by surgeons at the University Hospitals of Geneva (HUG) for the first time in Europe using American technology.

Believed to be only the tenth procedure of its kind performed in the world, the technology was developed by Second Sight, a California-based company in the US.

A tiny camera and transmitter are mounted in eyeglasses and an implanted receiver and a device containing 60 electrodes is secured to the retina with a wire the width of a human hair.

"This kind of implant is suitable for people who suffer from a well-defined malady, retinitis pigmentosa," said Avinoam Safran, chief doctor at HUG's Ophthalmology Department. The technology is not expected to restore vision completely to the patient, he noted.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.